Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma
Michael Rink(Marienkrankenhaus Hamburg), Shahrokh F. Shariat(Universitätszahnklinik Wien), Felix K.‐H. Chun(Universität Hamburg), Wassim Kassouf(McGill University), Mesut Remzi(Landesklinikum Korneuburg), Yair Lotan(Southwestern Medical Center), Kanishka Sircar(McGill University), Guru Sonpavde(AdventHealth Orlando), Douglas S. Scherr(Cornell University), Brian D. Robinson(Cornell University), Maxine Sun(Université de Montréal), Karim Bensalah(Centre Hospitalier Universitaire de Rennes), Wareef Kabbani(The University of Texas Southwestern Medical Center), Casey K. Ng(NewYork–Presbyterian Hospital), David A. Green(Columbia University), Evi Comploj(Ospedale di Bolzano), Andrea Haitel(University of Vienna), Vitaly Margulis(Southwestern Medical Center), Jens Hansen(Icahn School of Medicine at Mount Sinai), Pierre I. Karakiewicz(Université de Montréal), Nathalie Rioux‐Leclercq(Université de Rennes), Armin Pycha(Sigmund Freud Privatuniversität Wien), Charles C. Guo(The University of Texas MD Anderson Cancer Center), Jay D. Raman(Penn State Milton S. Hershey Medical Center), Eiji Kikuchi(Keio University)
Cited by 142
Related Papers
Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma
|Nature Medicine|2020|1k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2020|786
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based Chemotherapy
|Journal of Clinical Oncology|2011|686
Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma
|Cancer Cell|2021|624